Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
Accession Number
DB10990
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Toxoid
Description

Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primarly immunization. The vaccine contains Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]), which is a high molecular weight polymer prepared from the Haemophilus influenzae type b strain 20,752. These are heat inactivated and purified.

Synonyms
  • Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
HiberixInjection, powder, lyophilized, for solution10 ug/0.5mLIntramuscularGlaxoSmithKline Biologicals SA2009-08-242009-08-19Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
HiberixHaemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen (10 ug/0.5mL) + Water (1 mL/1mL)KitIntramuscularGlaxoSmithKline Biologicals SA2015-12-21Not applicableUs
Categories
UNII
C9R35M8XV6
CAS number
Not Available

Pharmacology

Indication

Indicated for active immunization in pediatric patients 15 months through 4 years of age as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Abetimus.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Acetylsalicylic acid.
ActeosideThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Afelimomab.
AlclometasoneThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alclometasone.
AldesleukinThe therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Aldesleukin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911072
RxNav
1300806

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionHaemophilus Influenzae Type B1
2CompletedPreventionMeningitis / Meningococcal sepsis1
2CompletedPreventionPlasmodium Infections1
3Active Not RecruitingPreventionInfections, Pneumococcal1
3Active Not RecruitingPreventionInfections, Pneumococcal / Vaccines, Pneumococcal1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Haemophilus Influenzae Type b Diseases / Pertussis / Poliomyelitis / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type b Diseases / Pertussis / Tetanus2
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type b Diseases / Poliomyelitis / Poliovirus / Tetanus / Viral Hepatitis B / Whooping Cough1
3CompletedPreventionDiphtheria / Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin / Haemophilus Infections / Haemophilus Influenzae Type B / Meningococcal Infections / Pertussis / Tetanus / Viral Hepatitis B / Whole Cell Pertussis2
3CompletedPreventionDiphtheria / Haemophilus Infections / Meningococcal Infections / Pertussis / Tetanus / Viral Hepatitis B1
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Haemophilus Influenzae Type b Diseases / Pertussis / Tetanus / Viral Hepatitis B / Whole Cell Pertussis2
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Hib Diseases / Neisseria Meningitidis Serogroup Diseases / Pertussis / Tetanus / Viral Hepatitis B / Whole Cell Pertussis2
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Hib Diseases / Pertussis / Tetanus / Viral Hepatitis B / Whole Cell Pertussis1
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type b (Hib) / Pertussis / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionDiphtheria / Hib Diseases / Meningococcal Infections / Neisseria Meningitidis Serogroup Diseases / Pertussis / Tetanus / Viral Hepatitis B1
3CompletedPreventionHaemophilus Influenzae Type B1
3CompletedPreventionHaemophilus Influenzae Type B / Neisseria Meningitidis1
3CompletedPreventionHaemophilus Influenzae Type b (Hib) Infection1
3CompletedPreventionInfections, Pneumococcal / Streptococcal Infections1
3CompletedPreventionInfections, Rotavirus / Rotavirus Vaccines1
3CompletedPreventionInfectious Disease by Haemophilus Influenzae Type b2
3CompletedPreventionPneumococcal Diseases / Streptococcal Infections / Streptococcus Pneumoniae1
3CompletedPreventionPneumococcal Diseases / Streptococcal Infections / Streptococcus Pneumoniae Vaccines2
3CompletedPreventionStreptococcal Infections / Streptococcus Pneumoniae1
3RecruitingPreventionMeningococcal Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular10 ug/0.5mL
KitIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on February 06, 2020 13:04